{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:00:51Z","timestamp":1791259251033,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104674","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:58:42Z","timestamp":1752839922000},"page":"104674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-3409","authenticated-orcid":false,"given":"Pierre","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Aup\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Chevrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Monard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Mirghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104674_bib0130","series-title":"United States Cancer Statistics [Internet]","article-title":"Cancers associated with human papillomavirus","author":"Anon","year":"2024"},{"key":"10.1016\/j.canrad.2025.104674_bib0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semradonc.2021.04.001","article-title":"Epidemiology of HPV related malignancies","volume":"31","author":"Scott-Wittenborn","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0140","doi-asserted-by":"crossref","first-page":"102603","DOI":"10.1016\/j.canep.2024.102603","article-title":"HPV-driven oropharyngeal cancer burden in Paris and its region (\u00cele-de-France) from 1981\u00a0TO 2021","volume":"91","author":"Mirghani","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canrad.2025.104674_bib0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.05.007","article-title":"Smoking impact on HPV driven head and neck cancer's oncological outcomes?","volume":"82","author":"Mirghani","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104674_bib0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canrad.2021.10.002","article-title":"Management of oropharyngeal squamous cell carcinoma","volume":"26","author":"Gr\u00e9goire","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104674_bib0165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: an ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0170","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0175","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1016\/j.annonc.2023.09.2003","article-title":"857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)","volume":"34","author":"Blanchard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0180","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.24.00119","article-title":"Radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: final results of the ORATOR randomized trial","volume":"42","author":"Nichols","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0185","doi-asserted-by":"crossref","first-page":"115343","DOI":"10.1016\/j.ejca.2025.115343","article-title":"Radiation vs. transoral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: primary analysis of the ORATOR2 randomized trial","volume":"220","author":"Palma","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104674_bib0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104674_bib0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104674_bib0200","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)\u2013A Trans-Tasman Radiation Oncology Group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104674_bib0205","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for Human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104674_bib0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijrobp.2022.06.057","article-title":"A prospective study of mucosal sparing radiation therapy in resected oropharyngeal cancer patients","volume":"115","author":"Anderson","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104674_bib0215","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2020.09.063","article-title":"Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer","volume":"109","author":"Sher","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104674_bib0220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0225","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2024.42.16_suppl.6006","article-title":"Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)","volume":"42","author":"Frank","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0230","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2Suppl","key":"10.1016\/j.canrad.2025.104674_bib0235","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, a randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104674_bib0240","doi-asserted-by":"crossref","first-page":"S840","DOI":"10.1016\/j.annonc.2022.07.777","article-title":"653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: q multicenter randomized phase II trial","volume":"33","author":"Mirghani","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104674_bib0245","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ijc.32804","article-title":"HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers","volume":"147","author":"Veyer","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2025.104674_bib0250","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:40:14Z","timestamp":1762368014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825000903"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104674","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104674"}}